47 completed, 30 recruiting, 17 active not recruiting, 13 not yet recruiting. 47 Phase 3, 25 Phase 2, 19 Phase 4, 9 Phase 1, 3 Not applicable.
Follow upadacitinib: new trials by email Literature Review of upadacitinib trials Research Report on upadacitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose Upadacitinib - Ulcerative Colitis (UC) | Phase 4 | Not yet recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 100 | 2026-11-15 | 2026-07-31 |
| A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis Secukinumab (IL-17i ), Upadacitinib (JAKi) - Axial Spondyloarthritis (AxSpA) | Phase 4 | Not yet recruiting | The University of Texas Health Science Center, Houston | 40 | 2026-11-01 | 2026-10-14 |
| Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Upadacitinib - UC - Ulcerative Colitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 50 | 2026-10-15 | 2026-09-24 |
| Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations Upadacitinib, Placebo - JAK1 GOF, STAT1 GOF | Phase 1 / Phase 2 | Not yet recruiting | Lisa Satter | 30 | 2026-10-01 | 2026-09-08 |
| Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study. Upadacitinib, Placebo - Lichen Penis Planus | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Nice | 56 | 2026-10-01 | 2026-10-01 |
| A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Upadacitinib 30mg Dose, Upadacitinib Matching Placebo - EoE, Eosinophilic Esophagitis | Phase 2 | Recruiting | University of North Carolina, Chapel Hill | 52 | 2026-09-30 | 2026-10-06 |
| Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis Etanercept, Adalimumab, Upadacitinib - Arthritis, Rheumatoid | Not yet recruiting | Tufts Medical Center | 18 | 2026-09-01 | 2026-07-22 | |
| A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers Upadacitinib, Tofacitinib, Baricitinib - Healthy Volunteers | Phase 1 | Recruiting | AbbVie | 60 | 2026-08-26 | 2026-09-28 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata Upadacitinib, Placebo - Severe Alopecia Areata | Phase 3 | Recruiting | AbbVie | 300 | 2026-08-24 | 2026-10-23 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis JAK inhibitor(tofacitinib/upadacitinib) as advised by the rheumatologist as add on to 25 mg methotrexate - Rheumatoid Arthritis (RA) | Phase 4 | Not yet recruiting | Sheikh Zayed Federal Postgraduate Medical Institute | 100 | 2026-07-05 | 2026-06-09 |
| A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa Upadacitinib - Hidradenitis Suppurativa (Acne Inversa) | Phase 2 | Active not recruiting | Peking Union Medical College | 50 | 2026-07-01 | 2026-07-27 |
| The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching Upadacitinib 15 MG - Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | RenJi Hospital | 44 | 2026-06-01 | 2026-07-01 |
| Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis Upadacitinib 15 MG [Rinvoq] - Axial Spondylarthritis (axSpA) | Phase 4 | Not yet recruiting | CARE ARTHRITIS LTD. | 200 | 2026-05-01 | 2026-02-06 |
| Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica Abrocitinib, Upadacitinib, Baricitinib - Atopic Dermatitis, Atopic Dermatitis (AD) | Not yet recruiting | Caja Costarricense de Seguro Social | 50 | 2026-05-01 | 2026-04-08 | |
| Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE） upadacitinib, Infliximab - Acute Severe Ulcerative Colitis | Phase 4 | Recruiting | Xijing Hospital of Digestive Diseases | 226 | 2026-04-20 | 2026-04-24 |
| Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT） Upadacitinib, Corticosteroid - Acute Severe Ulcerative Colitis | Phase 4 | Recruiting | Yongquan Shi | 46 | 2026-03-23 | 2026-06-15 |
| TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification - Crohn Disease (CD) | Phase 4 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 312 | 2026-03-01 | 2026-06-09 |
| A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants ABBV-722, Upadacitinib - Healthy Volunteer | Phase 1 | Completed | AbbVie | 16 | 2026-02-26 | 2026-08-04 |
| Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo - Ulcerative Colitis Acute | Phase 4 | Recruiting | Berinstein, Jeffrey | 110 | 2026-01-16 | 2026-02-02 |
Showing 20 of 122. Sign in to see all of them.
Arthritis, Rheumatoid (29) · Dermatitis, Atopic (25) · Crohn Disease (14) · Colitis, Ulcerative (13) · Arthritis (11) · Joint Diseases (11) · Musculoskeletal Diseases (11) · Arthritis, Psoriatic (10) · Axial Spondyloarthritis (6) · Alopecia Areata (5) · Lupus Erythematosus, Systemic (5) · Hidradenitis Suppurativa (4) · Inflammatory Bowel Diseases (4) · Psoriasis (4) · Spondylarthritis (4)
AbbVie (61) · Sixth Affiliated Hospital, Sun Yat-sen University (9) · Peking University People's Hospital (3) · Berinstein, Jeffrey (2) · CARE ARTHRITIS LTD. (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · University of California, San Francisco (2) · Xijing Hospital of Digestive Diseases (2) · AbbVie (prior sponsor, Abbott) (1) · Abu Dhabi Stem Cells Center (1) · Assiut University (1) · Atsushi Kawakami (1) · Caja Costarricense de Seguro Social (1) · Centre Hospitalier Universitaire de Nice (1) · Douglas D. Fraser (1)
United States (64) · China (46) · Spain (46) · Canada (44) · Hungary (40) · Italy (40) · Germany (39) · Japan (39) · United Kingdom (38) · Australia (35) · France (34) · Puerto Rico (34) · Belgium (33) · Poland (33) · South Korea (32)
Jeffrey Berinstein, MD, MSc (2) · Walter Maksymowych, Dr. (2) · Atsushi Kawakami, MD, PhD (1) · Chang-Keun Lee, MD (1) · Changhoon Lee, MD (1) · Dae Hyun Yu, MD (1) · Douglas D Fraser, MD, PhD, FRCPC (1) · Esperanza Naredo (1) · Eun Yeong Lee, MD (1) · Evan S Dellon, MD, MPH (1) · Georgios Filippou, MD (1)
PMID 40875187, PMID 36754548, PMID 37982966, PMID 37945286, PMID 34041702, PMID 31610021, PMID 36715850, PMID 37308218, PMID 33115760, PMID 36125701, PMID 36794283, PMID 37224198, PMID 38683479, PMID 39624020, PMID 41264726, PMID 41763462, PMID 29076110, PMID 35644166, PMID 35714786, PMID 37043227, PMID 37247226, PMID 38492903, PMID 38492904, PMID 38982567, PMID 39110139, PMID 39231444, PMID 39441580, PMID 40457140, PMID 40900410, PMID 41189093, PMID 42530735, PMID 31194885, PMID 33313898, PMID 34023008, PMID 34464029, PMID 34636000, PMID 34864911, PMID 34897366, PMID 34970731, PMID 35262646, PMID 35606663, PMID 36464141, PMID 36571701, PMID 36645051, PMID 36790041, PMID 37942921, PMID 38010661, PMID 38331400, PMID 38528257, PMID 38696027
2023 (12), 2016 (6), 2017 (6), 2015 (5), 2018 (4), 2019 (2), 2025 (2), 2014 (1), 4UH3TR003908 (1), K23DK134764 (1), R01DK146043 (1)